Dr. Jay R. Patel, MD
Ophthalmology (Ophthalmology Physician)
2619 E Colorado Blvd Ste 150
Pasadena, CA 91107
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 399
Licensed in California since 2013, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A127433 (first issued 2013; current) -
Cornea and External Diseases Specialist Physician
CA license A127433 (first issued 2013; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Azul Vision Inc (48 clinicians)
- California Eye Specialists Medical Group Inc (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 399
- Services billed
- 1,144
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 132 | 92 |
| Established patient office or other outpatient visit, 30-39 minutes | 62 | 60 |
| Removal of cataract with insertion of prosthetic lens | 58 | 50 |
| Established patient problem focused exam of visual system | 29 | 28 |
| Established patient complete exam of visual system | 27 | 25 |
| Exam of visual field with extended testing | 27 | 26 |
| Imaging of retina | 26 | 26 |
| Established patient office or other outpatient visit, 10-19 minutes | 19 | 14 |
| Imaging of optic nerve | 17 | 17 |
| Ultrasound scan to determine eye length and lens power | 15 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Pasadena, CA | 1,830 |
| Ofloxacin Other prescribers in Pasadena, CA | 1,459 |
| Latanoprost Other prescribers in Pasadena, CA | 696 |
| Timolol Maleate Other prescribers in Pasadena, CA | 251 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Pasadena, CA | 210 |
| Erythromycin (erythromycin base) Other prescribers in Pasadena, CA | 197 |
| Brimonidine Tartrate Other prescribers in Pasadena, CA | 179 |
| Restasis (cyclosporine) Other prescribers in Pasadena, CA | 147 |
| Cyclosporine Other prescribers in Pasadena, CA | 137 |
| Ketorolac Tromethamine Other prescribers in Pasadena, CA | 131 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 46 payments worth $2,262 in total to this clinician.
| Alcon Vision LLC | $865 |
|---|---|
| Sun Pharmaceutical Industries Inc. | $314 |
| Dompe US, Inc. | $268 |
| Tarsus Pharmaceuticals, Inc. | $198 |
| Sight Sciences, Inc. | $143 |
| Rxsight Inc | $136 |
| AbbVie Inc. | $131 |
| Glaukos Corporation | $121 |
| Food and Beverage | $2,262 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,500 in research payments for these studies, mostly to the institutions running them.
- OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
Oyster Point Pharma, Inc. · Recruiting · NCT07140783
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.